Cargando…

Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate

As a bisphosphonate, minodronate (MIN) is one of the strongest inhibitors of bone resorption. However, there have been no reports directly comparing the antiresorptive effects of monthly MIN with those of monthly risedronate (RIS). We enrolled 30 cases of osteoporosis (OP; 16 in the MIN group [mean...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamimura, Mikio, Nakamura, Yukio, Ikegami, Shota, Komatsu, Masatoshi, Uchiyama, Shigeharu, Kato, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Osteoporosis 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372746/ https://www.ncbi.nlm.nih.gov/pubmed/30775483 http://dx.doi.org/10.1016/j.afos.2016.07.002

Ejemplares similares

Bone alterations are associated with ankle osteoarthritis joint pain
por: Nakamura, Yukio, et al.
Publicado: (2016)

A case series of pregnancy- and lactation-associated osteoporosis and a review of the literature
por: Nakamura, Yukio, et al.
Publicado: (2015)

Knee Joint Pain Potentially Due to Bone Alterations in a Knee Osteoarthritis Patient
por: Komatsu, Masatoshi, et al.
Publicado: (2014)

Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study
por: Suzuki, Takako, et al.
Publicado: (2019)

Associations of self-reported height loss and kyphosis with vertebral fractures in Japanese women 60 years and older: a cross-sectional survey
por: Kamimura, Mikio, et al.
Publicado: (2016)

Joint Pain Undergoes a Transition in Accordance with Signal Changes of Bones Detected by MRI in Hip Osteoarthritis
por: Kamimura, Mikio, et al.
Publicado: (2013)

A Case with Atypical Clinical Course Diagnosed as Osteoarthritis, Osteonecrosis, Subchondral Insufficiency Fracture, or Rapidly Destructive Coxopathy
por: Nakamura, Yukio, et al.
Publicado: (2014)

The Pathophysiology and Progression of Hip Osteoarthritis Accompanied with Joint Pain are Potentially Due to Bone Alterations - Follow-up Study of Hip OA Patients
por: Kamimura, Mikio, et al.
Publicado: (2014)

The Pathophysiology of Primary Hip Osteoarthritis may Originate from Bone Alterations
por: Kamimura, Mikio, et al.
Publicado: (2013)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D(3) and alters values of parathyroid hormone, pentosidine, and bone metabolic markers
por: Kamimura, Mikio, et al.
Publicado: (2017)

Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study
por: Nakamura, Yukio, et al.
Publicado: (2015)

Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
por: Kamimura, Mikio, et al.
Publicado: (2018)

Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women
por: Nakamura, Yukio, et al.
Publicado: (2017)

Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis
por: Okazaki, R., et al.
Publicado: (2011)

Comparison in bone turnover markers during early healing of femoral neck fracture and trochanteric fracture in elderly patients
por: Ikegami, Shota, et al.
Publicado: (2009)

Early Changes in Bone Specific Turnover Markers During the Healing Process After Vertebral Fracture
por: Hashidate, Hiroyuki, et al.
Publicado: (2011)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats
por: Yano, Tetsuo, et al.
Publicado: (2021)

Anti-Nociceptive Effects of Elcatonin Injection for Postmenopausal Women with Back Pain: A Randomized Controlled Trial
por: Ikegami, Shota, et al.
Publicado: (2010)

Utility of monthly minodronate for osteoporosis after gastrectomy: Prospective multicenter randomized controlled trials
por: Hirota, Masashi, et al.
Publicado: (2021)

Minodronate for the treatment of osteoporosis
por: Ohishi, Tsuyoshi, et al.
Publicado: (2018)

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study
por: Cho, Yong Ho, et al.
Publicado: (2020)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: Moro-Álvarez, María J, et al.
Publicado: (2008)

Delayed wound healing after tooth extraction and self-reported kyphosis in Japanese men and women
por: Taguchi, Akira, et al.
Publicado: (2016)

The efficiency of risedronate in reducing bone resorption after total hip arthroplasty: a meta-analysis of randomized control trials at a minimum of 6 months’ follow-up
por: Yang, Liqing
Publicado: (2018)

Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients
por: Suzuki, Takako, et al.
Publicado: (2018)

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
por: Kamimura, Mikio, et al.
Publicado: (2019)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Influence on the bone mineral density and bone metabolism marker after the interruption and reinitiation of monthly minodronate therapy in postmenopausal women with osteoporosis
por: Okimoto, Nobukazu, et al.
Publicado: (2018)

Comment on “The efficiency of risedronate in reducing bone resorption after total hip arthroplasty: a meta-analysis of randomized control trials at a minimum of 6 months’ follow-up”
por: Kai Huang, M. M., et al.
Publicado: (2022)

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
por: McClung, Michael R., et al.
Publicado: (2012)

Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study
por: Sakai, A., et al.
Publicado: (2014)

The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis
por: Hasegawa, Eriko, et al.
Publicado: (2018)

Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene
por: Ohta, Hiroaki, et al.
Publicado: (2023)

Efficacy of denosumab therapy for neurofibromatosis type 1 with osteoporosis and history of fractures: a case report
por: Uehara, Masashi, et al.
Publicado: (2018)

Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
por: Tanaka, Mizue, et al.
Publicado: (2017)

Erratum to: Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study
por: Sakai, A., et al.
Publicado: (2014)

A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis
por: Soen, Satoshi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hacotc3n5glj1j9rqomkqbq1vo